Analysis of the relationship between serum miR-132-3p expression level and drug resistance in adult patients with epilepsy

doi:10.3877/cma.j.issn.2095-123X.2022.06.005

Abstract

Abstract:

Objective

To observe the expression level of serum miR-132-3p in adult patients with epilepsy and analyze its relationship with drug resistance.

Methods

One hundred and twenty-four adult patients with epilepsy admitted to Neurology Department of Xuzhou Central Hospital from February 2018 to April 2021 were selected as the research group, and another 120 healthy people during the same period were selected as the health group. Real time-quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression level of serum miR-132-3p. The expression levels of serum miR-132-3p in the two groups were compared. The drug resistance of epilepsy patients in the research group was observed, and the expression level of miR-132-3p in serum of epilepsy drug-resistant and non drug resistant patients in the research group were compared. Logistic regression analysis method was used to analyze the relationship between serum miR-132-3p expression and drug resistance.

Results

The expression level of serum miR-132-3p in the research group was higher than that in the healthy group (P<0.05). The drug resistance rate of epilepsy in the research group was 18.75% (21/112). The expression level of serum miR-132-3p in drug-resistant patients was higher than that in non drug resistant patients (P<0.05). Disease course, seizure frequency, smoking, drinking and serum miR-132-3p expression level were the influencing factors of drug resistance in the research group (OR>1, P<0.05).

Conclusion

The expression of miR-132-3p in serum of adult epileptic patients increases and is related to drug resistance of epilepsy. In addition, seizure frequency, family history, smoking, drinking, and the expression of miR-132-3p in serum all increase the risk of drug resistance of epilepsy.

Key words: Epilepsy, miR-132-3p, Drug resistance

Mengwei Hao, Zhen Chen, Tao Wei, Hui Zhang. Analysis of the relationship between serum miR-132-3p expression level and drug resistance in adult patients with epilepsy[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(06): 344-348.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2022.06.005

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2022/V12/I06/344

Figures/Tables 4

References 20

[1]	Beghi E. The epidemiology of epilepsy[J]. Neuroepidemiology, 2020, 54(2）: 185-191.
[2]	Thijs RD, Surges R, O'Brien TJ, et al. Epilepsy in adults[J]. Lancet, 2019, 393(10172）: 689-701.
[3]	Yoo JY, Panov F. Identification and treatment of drug-resistant epilepsy[J]. Continuum (Minneap Minn）, 2019, 25(2）: 362-380.
[4]	Herrera-Espejo S, Santos-Zorrozua B, Álvarez-González P, et al. A systematic review of microRNA expression as biomarker of late-onset alzheimer's disease[J]. Mol Neurobiol, 2019, 56(12）: 8376-8391.
[5]	Dusaulcy R, Handgraaf S, Visentin F, et al. miR-132-3p is a positive regulator of alpha-cell mass and is downregulated in obese hyperglycemic mice[J]. Mol Metab, 2019, 22: 84-95.
[6]	谭启富,李龄,吴承远.癫痫外科学[M]. 2版.北京:人民卫生出版社, 2012: 20-26.
[7]	何权瀛,高莹慧.关于吸烟问题若干名词定义[J].中华结核和呼吸杂志, 2009, 32(1）: 56.
[8]	吕晓霞,许伟华.饮酒与疾病[M].济南:山东大学出版社, 2007: 31-36.
[9]	贾建平.神经病学[M].6版.北京:人民卫生出版社, 2008: 15-17.
[10]	Wang XP, Wang HJ, Zhu LN, et al. Risk factors for drug-resistant epilepsy: a systematic review and meta-analysis[J]. Medicine (Baltimore）, 2019, 98(30）: e16402.
[11]	杨艳丽,胡曦,舒东,等. ABCC2基因多态性与耐药性癫痫的相关性分析[J].中国医师杂志, 2018, 20(6）: 836-838, 843.
[12]	Wang Y, Chen Z. An update for epilepsy research and antiepileptic drug development: toward precise circuit therapy[J]. Pharmacol Ther, 2019, 201: 77-93.
[13]	Organista-Juárez D, Jiménez A, Rocha L, et al. Differential expression of miR-34a, 451, 1260, 1275 and 1298 in the neocortex of patients with mesial temporal lobe epilepsy[J]. Epilepsy Res, 2019, 157: 106188.
[14]	Li QK, Liu YK, Li JW, et al. Circ-sirt1 inhibits growth and invasion of gastric cancer by sponging miR-132-3p/miR-212-3p and upregulating sirt1 expression[J]. Neoplasma, 2021, 68(4）: 780-787.
[15]	Assmann TS, Milagro FI, Martínez JA. Crosstalk between microRNAs, the putative target genes and the lncRNA network in metabolic diseases[J]. Mol Med Rep, 2019, 20(4）: 3543-3554.
[16]	van den Berg MMJ, Krauskopf J, Ramaekers JG, et al. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders[J]. Prog Neurobiol, 2020, 185: 101732.
[17]	魏宜功,王诚,周焜,等.以癫痫发作为首发症状的颞叶病变患者术前脑电图特征及对预后的临床指导意义[J].立体定向和功能性神经外科杂志, 2019, 32(5）: 257-262.
[18]	董晓杰,曾宽,田勤卿.低级别胶质瘤合并癫痫患者手术预后相关影响因素分析[J].医学临床研究, 2019, 36(8）: 1586-1588.
[19]	Qasim H, Alarabi AB, Alzoubi KH, et al. The effects of hookah/waterpipe smoking on general health and the cardiovascular system[J]. Environ Health Prev Med, 2019, 24(1）: 58.
[20]	Jorge RE, Li R, Liu X, et al. Treating alcohol use disorder in U.S. veterans: the role of traumatic brain injury[J]. J Neuropsychiatry Clin Neurosci, 2019, 31(4）: 319-327.

组别	例数	性别[例（%）]		年龄（岁，Mean±SD）	BMI（kg/m²，Mean±SD）
组别	例数	男	女	年龄（岁，Mean±SD）	BMI（kg/m²，Mean±SD）
研究组	124	85（68.55）	39（31.45）	39.21±7.62	22.36±4.12
健康组	120	84（70.00）	36（30.00）	38.55±7.49	21.74±4.31
χ²/t值		0.060		0.682	1.149
P值		0.806		0.496	0.252

组别	例数	性别[例（%）]		年龄（岁，Mean±SD）	BMI（kg/m²，Mean±SD）
组别	例数	男	女	年龄（岁，Mean±SD）	BMI（kg/m²，Mean±SD）
研究组	124	85（68.55）	39（31.45）	39.21±7.62	22.36±4.12
健康组	120	84（70.00）	36（30.00）	38.55±7.49	21.74±4.31
χ²/t值		0.060		0.682	1.149
P值		0.806		0.496	0.252

基因	上游	下游
miR-132-3p	5'-CGTAACAGTCTACAGCCATG-3'	5'-TGGTGTCGTGGAGTCG-3'
U6	5'-CTCGCTTCGGCAGCACA-3'	5'-AACGCTTCACGAATTTGCGT-3'

基因	上游	下游
miR-132-3p	5'-CGTAACAGTCTACAGCCATG-3'	5'-TGGTGTCGTGGAGTCG-3'
U6	5'-CTCGCTTCGGCAGCACA-3'	5'-AACGCTTCACGAATTTGCGT-3'

因素		耐药（n=21）	非耐药（n=91）	χ²/t值	P值
性别[例（%）]
	男	15（71.43）	63（69.23）	0.039	0.843
	女	6（28.57）	28（30.77）	0.039	0.843
年龄（岁，Mean±SD）		40.18±7.34	38.27±7.28	1.085	0.280
体质量指数（kg/m²，Mean±SD）		23.47±4.56	22.06±4.32	1.339	0.183
癫痫发作类型[例（%）]				0.746	0.388
	GTCS	14（66.67）	69（75.82）
	CPS	4（19.05）	12（13.19）
	SPS	3（14.29）	10（10.99）
家族史[例（%）]				1.395	0.238
	有	4（19.05）	9（9.89）
	无	17（80.95）	82（90.11）
病程（年，Mean±SD）		8.73±1.63	4.24±0.58	21.298	<0.001
发作频率（次/月，Mean±SD）		4.29±0.76	2.15±0.37	19.126	<0.001
吸烟[例（%）]				12.432	<0.001
	有	16（76.19）	31（34.07）
	无	5（23.81）	60（65.93）
饮酒[例（%）]				18.289	<0.001
	有	15（71.43）	21（23.08）
	无	6（28.57）	70（76.92）
血清miR-132-3p表达（Mean±SD）		1.80±0.31	1.51±0.26	4.440	<0.001

Please choose a citation manager

Content to export